Shanghai MicuRx Pharmaceutical (SHA:688373) completed the third phase of the clinical trial of oral cantizolid tablets, or MRX-4, in China.
Study results showed that MRX-4 is effective in treating complex skin and soft tissue infections, with the tablets showing good patient safety and tolerability, according to a Thursday filing with the Shanghai bourse.
Meanwhile, the international third phase trial of the medication for treating diabetic foot infection is ongoing.
Shares of the drugmaker were down 1% Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.